In a bid to strengthen its haematological oncology pipeline, AstraZeneca has agreed to acquire TeneoTwo, a biotech focused on bispecific antibody therapies. The agreement, worth up to US$1.27 B, grants AstraZeneca access to TeneoTwo’s Phase I CD19xCD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma. The deal marks the third acquisition of an asset from the company originally named Teneobio, after selling its two other bispecific companies to AbbVie and Amgen in 2021.